

NANO SHIPMENT UPDATE AND REDUCTION IN ORDER BACKLOG

Back log reduced with New Order delivery time less than 4 weeks necessary

Adelaide, Australia, 29th May 2020: Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode x-ray technology for health and security markets globally, provides the following Market Update on progress of production and shipping of the *Carestream DRX Revolution Nano* (the **Nano**).

Key Points

- **May 2020 - \$0.5m of Nano units built, shipped and invoiced**
- **\$2.2m Nano built, shipped and invoiced since January 2020**
- **Major reduction in backlog of existing orders to under \$1.0 million**
- **New Order delivery time now less than 4 weeks – required for COVID-19 customers**

Since 1 May 2020, \$0.5 million of Nano units have been shipped globally to countries in Europe, North America, and Asia as well as domestically. This has reduced the backlog of existing orders for the Nano to less than \$1.0 million which will all be delivered in the month of June. The total Nano units shipped and invoiced since January 2020 is now \$2.2 million.

As previously announced, COVID-19 has significantly changed the mobile X-ray market across the world with delivery times required to be less than 4 weeks to meet the urgent need for imaging of infected patients. This demand has been driven largely by government health agencies using emergency procurement processes different from the normal purchasing or tendering cycles of 8-12 week delivery.

In order to ramp up production and reduce delivery times, Micro-X has invested significantly in inventory, capex and additional resources supported by funds from the recent \$15.0 million Placement and Entitlement Offer. With delivery times for new orders now at 4 weeks or less, this is expected to increase the potential demand for new Purchase Orders of the Nano.

Micro-X's Managing Director, Peter Rowland, commented:

"The team at Micro-X has worked tremendously hard to reach our goal of reducing the backlog of existing orders and to enable us to offer delivery times for future orders of less than 4 weeks. We believe this will be a key factor in maintaining the momentum of growth in new Nano purchase orders to support health care facilitates internationally in their response to COVID-19."

This ASX Announcement is authorised by the Board of Micro-X.

– ENDS –

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for the global health and security markets, based on proprietary cold cathode, carbon nanotube emitter technology. The electronic control of emitters with this technology enables X-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. The Company has its core R&D, engineering and production capability at its facility in Adelaide, Australia.

The Company's first product, the *Carestream DRX Revolution Nano*, is an ultra-lightweight digital medical x-ray system for the rapidly expanding mobile x-ray market in hospitals and healthcare. The *Carestream DRX Revolution Nano* holds 510(k) and CE Mark certifications and is sold commercially in a number of global markets by the Company's exclusive distributor, Carestream Health, Inc. The Company has a portfolio of innovative products in development, aimed at customer solutions where there is little or no competition. This includes the Mobile Backscatter Imager

or MBI which will image Improvised Explosive Devices for airport security, defence and counter-terrorism applications. The MBI is being jointly developed in partnership with Thales, a global supplier of defence and security technology systems, who are providing technical support and \$10 million of funding.

CONTACTS

Micro-X Limited	Investor Enquiries
<p>Peter Rowland Managing Director Tel: +61 8 7099 3966 E: admin@micro-x.com</p>	<p>David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com</p>